Anaphylaxis to sublingual immunotherapy

Dunsky, Eliot H.; Goldstein, Michael S.; Dvorin, Donald J.; Belecanech, George A.

doi:10.1111/j.1398-9995.2006.01137.x

Cited by 119 publications

(66 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even when given at relevant doses, SLIT seems to be of a lower clinical efficacy as traditional injection immunotherapy [55][56][57]. It requires numerous, often daily applications for prolonged periods and also exhibits side-effects [37][38][39][40][41]. Furthermore, the immunological mechanisms behind SLIT are not understood and further elucidation is limited as long as crude allergen extracts are used, which make a systematic molecular and cellular analysis difficult, if not impossible.…”

Section: Past and Present Attempts For The Improvement Of Allergen-spmentioning

confidence: 99%

See 1 more Smart Citation

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Focke

Swoboda

Marth

et al. 2010

Clin Experimental Allergy

101

View full text Add to dashboard Cite

SummaryAllergen-specific immunotherapy (SIT) is the only specific and disease-modifying approach for the treatment of allergy but several disadvantages have limited its broad applicability. We argue that the majority of the possible disadvantages of SIT such as unwanted effects, poor efficacy and specificity as well as inconvenient application are related to the poor quality of natural allergen extracts, which are the active ingredients of all currently available allergy vaccines. Because of the progress made in the field of molecular allergen characterization, new allergy vaccines based on recombinant allergens, recombinant hypoallergenic allergen derivatives and allergen-derived T cell peptides have entered clinical testing and hold promise to reduce the side-effects and to increase the specificity as well as the efficacy of SIT. Here, we present a refined immunotherapy concept, which is based on the use of peptides derived from allergen surfaces that exhibit reduced, allergen-specific IgE as well as T cell reactivity. These peptides when fused to non-allergenic carriers give rise to allergen-specific protective IgG responses with T cell help from a non-allergenic carrier molecule. We summarize the experimental data demonstrating that such peptide vaccines can bypass allergen-specific IgE as well as T cell activation and may be administered at high doses without IgE-and T cell-mediated side-effects. Should these peptide vaccines prove efficacious and safe in clinical trials, it may become possible to develop convenient, safe and broadly applicable forms of SIT as true alternatives to symptomatic, drug-based allergy treatment.

show abstract

Section: Past and Present Attempts For The Improvement Of Allergen-spmentioning

confidence: 99%

“…The sublingual forms of treatment show a lower rate of side-effects than injection immunotherapy. However, SLIT requires frequent self-administration and significant sideeffects may still occur [37][38][39][40][41].…”

Section: Factors Limiting the Broad Application Of Allergen-specific mentioning

confidence: 99%

Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

Focke

Swoboda

Marth

et al. 2010

Clin Experimental Allergy

101

View full text Add to dashboard Cite

show abstract

“…Two recent clinical cases on anaphylactic reactions following SLIT have been published. However, one case was on latex immunotherapy and the other on an ill-defined multi-allergen vaccine (1725,1726).…”

Section: Sublingual Immunotherapymentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,867

1,761

View full text Add to dashboard Cite

“…of severe adverse events after SLIT administration had asthma, a further potential risk factor as for subcutaneous treatment [47][48][49][50][51] (Table 4). The first case involved a mixture of multiple extracts of different allergens.…”

Section: Sublingual Immunotherapymentioning

confidence: 99%